A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism

Alzheimer's Research and Therapy

Volumn 9, Issue 1, 2017, Pages

  Daugherty, Daniel ^a   Goldberg, Joshua ^a   Fischer, Wolfgang ^a   Dargusch, Richard ^a   Maher, Pamela ^a   Schubert, David ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Alzheimer's disease; Bioinformatics; Drug candidate; Gene expression; Metabolomics

Indexed keywords

ADENYLATE KINASE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CAD 31; CLUSTERIN; DOUBLECORTIN; INITIATION FACTOR 2ALPHA; NEUROPROTECTIVE AGENT; PRESENILIN 1; SEQUESTOSOME 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; FATTY ACID; INITIATION FACTOR 2; NEUROLEPTIC AGENT;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENCEPHALITIS; ENERGY METABOLISM; FATTY ACID METABOLISM; INFLAMMATION; MEMORY DISORDER; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTOGENESIS; ANIMAL; CELL CULTURE; COMPLICATION; DOSE RESPONSE; DRUG EFFECT; FEAR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MAZE TEST; METABOLISM; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SYNTHESIS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPSYCHOTIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUKARYOTIC INITIATION FACTOR-2; FATTY ACIDS; FEAR; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; MAZE LEARNING; MICE; MICE, TRANSGENIC; NEURONS; PRESENILIN-1; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 85023750013     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-017-0277-3     Document Type: Article

References (66)

1. Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, et al. A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One. 2011;6(12):e27865.
2. Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther. 2013;5(3):25.
3. Prior M, Chiruta C, Currais A, Goldberg J, Dargusch R, Maher P, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014;5(7):503-13.
4. Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, et al. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016;12(6):678-86.
5. Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, et al. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging. 2015;7(11):937-55.
6. Olin D, MacMurray J, Comings DE. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. Neurosci Lett. 2005;381(3):275-8.
7. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, et al. Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2(12):e355.
8. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, et al. Validation of a 2-day water maze protocol in mice. Behav Brain Res. 2009;196(2):220-7.
9. Belzung C, Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res. 2001;125(1-2):141-9.
10. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 1987;92(2):180-5.
11. Thompson RF, Krupa DJ. Organization of memory traces in the mammalian brain. Annu Rev Neurosci. 1994;17:519-49.
12. Kim JJ, Jung MW. Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci Biobehav Rev. 2006;30(2):188-202.
13. Bangasser DA, Waxler DE, Santollo J, Shors TJ. Trace conditioning and the hippocampus: the importance of contiguity. J Neurosci. 2006;26(34):8702-6.
14. Maren S, Fanselow MS. The amygdala and fear conditioning: has the nut been cracked? Neuron. 1996;16(2):237-40.
15. Rogan MT, LeDoux JE. Emotion: systems, cells, synaptic plasticity. Cell. 1996;85(4):469-75.
16. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
17. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem. 2008;105(4):1336-45.
18. Lanni C, Stanga S, Racchi M, Govoni S. The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders. Curr Pharm Des. 2010;16(6):698-717.
19. Abe K, Takayanagi M, Saito H. Effects of recombinant human basic fibroblast growth factor and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Jpn J Pharmacol. 1990;53(2):221-7.
20. Rossler OG, Giehl KM, Thiel G. Neuroprotection of immortalized hippocampal neurones by brain-derived neurotrophic factor and Raf-1 protein kinase: role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase. J Neurochem. 2004;88(5):1240-52.
21. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci (Lond). 2006;110(2):167-73.
22. Nakajo Y, Miyamoto S, Nakano Y, Xue JH, Hori T, Yanamoto H. Genetic increase in brain-derived neurotrophic factor levels enhances learning and memory. Brain Res. 2008;1241:103-9. A published erratum appears in Brain Res. 2009;1263:192.
23. Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets. 2004;8(5):391-9.
24. Tan S, Schubert D, Maher P. Oxytosis: a novel form of programmed cell death. Curr Topics Med Chem. 2001;1(6):497-506.
25. Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function by fisetin. In: Parker L, Sies H, Eggersdorfer M, Cardenas E, editors. Micronutrients and brain health. Boca Raton, FL: CRC Press; 2010. p. 189-206.
26. Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 2007;1173:117-25.
27. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 1994;77(6):817-27.
28. Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374-95.
29. Tan S, Somia N, Maher P, Schubert D. Regulation of antioxidant metabolism by translation initiation factor-2α. J Cell Biol. 2001;152(5):997-1006.
30. Simonsen A, Cumming RC, Brech A, Isakson P, Schubert DR, Finley KD. Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult Drosophila. Autophagy. 2008;4(2):176-84.
31. Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res. 2009;50(Suppl):S138-43.
32. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305(13):1322-6.
33. Currais A, Fischer W, Maher P, Schubert D. Intraneuronal protein aggregation as a trigger for inflammation and neurodegeneration in the aging brain. FASEB J. 2017;31(1):5-10.
34. Currais A, Quehenberger O, Armando AM, Daugherty D, Maher P, Schubert D. Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis. 2016;2:16012.
35. Valera E, Dargusch R, Maher PA, Schubert D. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. J Neurosci. 2013;33(25):10512-25.
36. Ma L, Li Y, Wang R. Drebrin and cognitive impairment. Clin Chim Acta. 2015;451(Pt B):121-4.
37. Minatohara K, Akiyoshi M, Okuno H. Role of immediate-early genes in synaptic plasticity and neuronal ensembles underlying the memory trace. Front Mol Neurosci. 2016;8:78.
38. Devenish RJ, Prescott M, Boyle GM, Nagley P. The oligomycin axis of mitochondrial ATP synthase: OSCP and the proton channel. J Bioenerg Biomembr. 2000;32(5):507-15.
39. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543-50.
40. Chiruta C, Schubert D, Dargusch R, Maher P. Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem. 2012;55(1):378-89.
41. Zahs KR, Ashe KH. 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 2010;33(8):381-9.
42. Wollen KA. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010;15(3):223-44.
43. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005;18(3):602-17.
44. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297(5868):681-3.
45. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009;29(7):1977-86.
46. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-4.
47. Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer's disease. Neurobiol Dis. doi: 10.1016/j.nbd.2016.07.007.
48. Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal. 2011;15(6):1607-38.
49. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol. 2010;45(1):75-9.
50. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation? J Alzheimers Dis. 2009;16(4):833-43.
51. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev. 2009;61(2):89-104.
52. Won JC, Park CY, Oh SW, Lee ES, Youn BS, Kim MS. Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS One. 2014;9(7):e103351.
53. Endres K, Reinhardt S. ER-stress in Alzheimer's disease: turning the scale? Am J Neurodegener Dis. 2013;2(4):247-65.
54. Kim H, Moon SY, Kim JS, Baek CH, Kim M, Min JY, et al. Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis. Am J Physiol Renal Physiol. 2015;308(3):F226-36.
55. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett. 2002;324(3):209-12.
56. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, Pai B, et al. The Arc of synaptic memory. Exp Brain Res. 2010;200(2):125-40.
57. Rudinskiy N, Hawkes JM, Betensky RA, Eguchi M, Yamaguchi S, Spires-Jones TL, et al. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nat Neurosci. 2012;15(10):1422-9.
58. Beck SJ, Guo L, Phensy A, Tian J, Wang L, Tandon N, et al. Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease. Nat Commun. 2016;7:11483.
59. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. 2009;59(2):293-315.
60. Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res. 2010;49(1):61-75.
61. Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-l-carnitine. Ann N Y Acad Sci. 2005;1053:153-61.
62. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21-43.
63. Couttas TA, Kain N, Daniels B, Lim XY, Shepherd C, Kril J, et al. Loss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun. 2014;2:9.
64. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging. 2010;31(3):398-408.
65. Wake Forest University Health Sciences. Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease (BEAM). ClinicalTrials.gov identifier: NCT02984540. Registered on 30 Nov 2016.
66. Bredesen DE. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY). 2014;6(9):707-17.